Cao Ye-Min, Wang Yu-Zhen, Pei Xiao-Hua, Yang Bo-Hua, Zhao Cheng, Fang Yu-Dong, Que Hua-Fa, Jiang Yu-Feng, Xu Xu-Ying, Xia Cheng-Yong, Zhang Jian-Qiang, He Chun-Hong, Ma Li-Ren
Shanghai Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine/Shanghai Institute of Integrated Traditional Chinese and Western Medicine and Vascular Diseases Shanghai 200086, China.
Xiamen Hospital of Beijing University of Chinese Medicine Xiamen 361001, China.
Zhongguo Zhong Yao Za Zhi. 2021 Dec;46(24):6568-6573. doi: 10.19540/j.cnki.cjcmm.20211009.501.
Tongsaimai Tablets/Capsules are composed of Lonicerae Japonicae Flos, Angelicae Sinensis Radix, Achyranthis Bidentatae Radix, Codonopsis Radix, Dendrobii Caulis, Astragali Radix, Scrophulariae Radix, and Glycyrrhizae Radix et Rhizoma, and are effective in promoting blood circulation, removing blood stasis, supplementing Qi, and nourishing Yin. It is widely used in the treatment of peripheral vascular diseases. With 40 years of clinical application, it has accumulated substantial research data and application experience. Its good clinical efficacy and pharmacoeconomic benefits in improving the clinical symptoms of peripheral vascular diseases have been confirmed by relevant research. Meanwhile, this drug has also been recommended by many expert consensus, guidelines, and teaching materials, serving as one of the most commonly used Chinese patent medicines in clinical practice. To further improve the understanding of the drug among clinicians and properly guide its clinical medication, the China Association of Chinese Medicine took the lead and organized experts to jointly formulate this expert consensus. Based on the questionnaire survey of clinicians and the systematic review of research literature on Tongsaimai Tablets/Capsules with clinical problems in the PICO framework, the consensus, combined with expert experience, concludes recommendations or consensus suggestions by GRADE system with the optimal evidence available through the nominal group technique. This consensus defines the indications, usage, dosage, course of treatment, medication time, combined medication, and precautions of Tongsaimai Tablets/Capsules in the treatment of peripheral vascular diseases, and explains the safety of its clinical application. It is recommended for clinicians and pharmacists in the peripheral vascular department(vascular surgery), traditional Chinese medicine surgery(general surgery), and endocrinology department of hospitals at all levels in China.
通塞脉片/胶囊由金银花、当归、牛膝、党参、石斛、黄芪、玄参、甘草组成,具有活血化瘀、益气养阴之功效,广泛用于治疗周围血管疾病。经过40年的临床应用,积累了大量的研究数据和应用经验。其在改善周围血管疾病临床症状方面的良好临床疗效和药物经济学效益已得到相关研究的证实。同时,该药物也被多个专家共识、指南和教材推荐,是临床常用的中成药之一。为进一步提高临床医生对该药物的认识,规范其临床用药,中华中医药学会牵头组织专家共同制定本专家共识。基于对临床医生的问卷调查以及运用PICO框架对通塞脉片/胶囊治疗临床问题的研究文献进行系统评价,结合专家经验,通过名义组技术采用GRADE系统依据现有最佳证据得出推荐意见或共识建议。本共识明确了通塞脉片/胶囊治疗周围血管疾病的适应证、用法用量、疗程、用药时间、联合用药及注意事项,并阐述了其临床应用的安全性。推荐给我国各级医院周围血管科(血管外科)、中医外科(普通外科)及内分泌科的临床医生和药师参考。